RxDoctor Payments Data

Nardo Zaias

Miami Beach, FLNPI 1952343923

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 35.7% of the total. Reporting peaked in 2023 at $1,144 and has fallen 89.8% since, to $117 in 2024.

$4,816in general payments, 2019–2025

Across 216 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$517
  • Journey Medical Corporation$353
  • Lilly USA, LLC$312
  • Johnson & Johnson$258
  • Sanofi$230
  • plus $1K from 18 others
$29,576in research payments, 2019–2025

Across 6 payments — averaging $4929.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$30K

What the payments were for

  • Food & beverage$4,816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →